Cerus (cers)

adolar

MEMBER
Registrato
9/6/00
Messaggi
49.069
Punti reazioni
1.635
Ecco l'altra compagnia che sviluppa il vaccino anticancro con medi
Overview of the company
Cerus Corp. is developing medical products based on a platform technology that prevents nucleic acid (DNA & RNA) replication, allowing for the development of systems to inactivate viruses, bacteria and other pathogens in blood components. For the 9 months ended 9/30/03, revenues fell 11% to $6.1M. Net loss rose 16% to $48.1M. Revenues reflect the absence of $5M milestone payment from Baxter. Higher loss reflects increased R&D expenditures.
Get CERS's latest analyst recommendation.
This summary was updated 25 November 2003

Earnings (MRQ) -0.46 N/A
Earnings (TTM) -3.15 N/A
Earnings growth rate - 5 year N/A N/A


Other per share data. Other per share data $Value
Revenue (TTM) 0.50
Book value (MRQ) 2.84
Cash (MRQ) 5.58 ;)

P/E Ratio (TTM) N/A 43.38 30.78 24.40
P/E High - Last 5 Years N/A 63.09 57.17 45.49
P/E Low - Last 5 Years N/A 26.78 21.47 16.26
Price to Tangible Book (MRQ) 1.22 N/A N/A N/A
Price to Book (MRQ) 1.22 6.11 5.57 4.37 ;)
Price to Sales (TTM) 6.92 11.22 6.24 3.39 :eek:
Price to Cash Flow (TTM) N/A 32.63 28.13 17.68
Price to Free Cash Flow (TTM) N/A 40.85 41.05 29.36
% Owned Institutions 51.11 (discretamente presenti)
Quick ratio (MRQ) 1.79 3.64 1.84 1.27
Current ratio (MRQ) 1.86 4.49 2.46 1.77
Long term debt to equity (MRQ) 0.00 0.32 0.33 0.68
Total debt to equity (MRQ) 0.87 0.35 0.41 0.85

% Return on Equity (TTM) -99.34 2.04 15.08 18.74 :eek:
% Interest Coverage (TTM) N/A -2.53 13.76 11.90
 
:rolleyes:
 

Allegati

  • mchartisapi.png
    mchartisapi.png
    19 KB · Visite: 184
torna a 70:D:p:eek::rolleyes::p;)
 

Allegati

  • mchartisapi.png
    mchartisapi.png
    21 KB · Visite: 182
a ridosso dei minimi annuali. Fallisce? Si diversifica nel settore lattiero caseario?:D
Last close $3.46
52 week high $13.20
52 week low $3.35
Year to date price change (YTD) 23.79%
Change relative to S&P 500 (YTD) 23.52%
Beta 1.15


Share related. Share-related Value
Market cap $76 M
Total shares outstanding 22.06 M
Float 20.30 M
 
At Cerus Corporation (Nasdaq: CERS), we have developed a platform technology (Helinx®) that prevents nucleic acid (DNA and RNA) replication. The Company's initial application of this technology is the development of the INTERCEPT Blood System to inactivate viruses, bacteria and other pathogens in the blood components used for transfusion - platelets, plasma and red blood cells.

Current blood testing procedures are not able to detect all known or emerging pathogens in blood. As a result, thousands of infections result from transfusions each year. Our goal is to eliminate these infections and other adverse transfusion reactions through the use of the INTERCEPT Blood System, which we have co-developed with our marketing and distribution partner Baxter Healthcare Corporation. With more than 90 million units of blood donated worldwide every year, the potential market opportunity for Cerus is significant.

Cerus is pusuing other therapeutic applications of Helinx technology to treat and prevent serious diseases. Current studies are evaluating the use of Helinx to improve the outcome of stem cell transplanation procedures and to protect immunocompromised organ transplant patients against Epstein Barr virus (EBV) infection.

At Cerus, scientific excellence guides everything we do. Our expertise is based on thirty years of experience with the chemistry of DNA - the blueprint of life - and our future depends on the application of this knowledge to fundamental problems in medicine. Our scientific goals are twofold: the development of important new medical technologies and biopharmaceuticals, and strong growth for both our company and our stockholders.


--------------------------------------------------------------------------------

Highlights
INTERCEPT Blood System for platelets approved in Europe and Canada, first commercially available pathogen inactivation system for platelets
INTERCEPT Blood System developed to prevent transmission of viruses, bacteria, and other pathogens through blood products
Pipeline of therapeutics and vaccines based on proprietary Helinx technology
Strong corporate partnerships and large target markets
 
Cerus scientists have developed a family of novel small molecules which target and crosslink nucleic acids. These Helinx® compounds cross cell walls or viral membranes, then bind to and crosslink nucleic acids (DNA and RNA), preventing their replication.

By disrupting the ability of the genetic blueprints in DNA and RNA to be expressed and reproduced, Helinx compounds prevent viruses, bacteria and other pathogens from causing infection. The Helinx compounds also prevent the proliferation of white blood cells which are associated with a variety of adverse transfusion reactions.

The major blood components used for transfusion - platelets, plasma, and red blood cells - do not contain nuclear DNA or RNA, and therefore retain their biological utility after Helinx inactivation treatment. This selective, targeted approach to blood safety is the key to Cerus' development of the

The market for blood products is over $10 billion and growing, and with more than 90 million units of blood donated world-wide every year, the need for methods to improve the safety of blood products is truly significant.

Cerus and its marketing and distribution partner, Baxter Healthcare Corporation, a world leader in the manufacturing and marketing of blood collection and transfusion equipment, are developing the INTERCEPT Blood System to meet this need and to realize this tremendous opportunity.

The INTERCEPT Blood System is designed to be simple and to fit within the operations of the world's blood centers. The system includes a sterile disposable set pre-filled with Helinx® inactivation compounds. The INTERCEPT Blood System for platelets and the INTERCEPT Blood System for plasma employ amotosalen HCl (S-59), which is activated by an ultraviolet light source. The INTERCEPT Blood System for red blood cells utilizes S-303, which is activated by the change in pH created by the introduction of red blood cells into the disposable set.


Molto interessante. Praticamente è una molecola che impedisce la diffusione di virus all'interno delle cellule e impedisce lo sviluppo di infezioni virali nel sangue da donatori;)
 
pipeline INTERCEPT

INTERCEPT Development Programs Status
INTERCEPT Blood System for Platelets - Europe LAUNCHED
INTERCEPT Blood System for Platelets - U.S. REGULATORY REVIEW*
INTERCEPT Blood System for Plasma PHASE III
INTERCEPT Blood System for Red Blood Cells R&D
* Supplementary clinical trial required to complete PMA.

--------------------------------------------------------------------------------

The INTERCEPT Blood System for platelets has received final CE Mark approval, and sales are underway in Europe.

Cerus has completed its Phase III SPRINT trial for the evaluation of its INTERCEPT Blood System for platelets in the U.S., and anticipates a supplementary trial to complete the modular PMA submission process necessary for marketing approval.

The three protocols for Phase III evaluation of the INTERCEPT Blood System for plasma are nearly complete.

Two Phase I studies and one Phase II study of the INTERCEPT Blood System for red blood cells have been completed. The company is currently evaluating product and process enhancements that might allow reinitiation of clinical trials.
 
Cerus is developing new blood processing systems to meet the demand for a safer blood supply. The INTERCEPT Blood System inactivates a broad spectrum of pathogens that can be found in blood transfusion products. Today's screening and testing procedures provide a measure of safety, but they target only a few of the most serious contaminants and offer no protection against new and emerging pathogens or new strains of existing diseases. The INTERCEPT Blood System products under development do not rely on testing and can work proactively by preventing the replication of a wide range of viruses and bacteria.


--------------------------------------------------------------------------------


Limitations of current testing procedures. Today's testing procedures, specific to a limited number of infectious agents, are not 100% effective and do not protect against the transmission of many other known contaminants or emerging pathogens. :eek:
 
Cerus is developing the INTERCEPT Blood System, based on its Helinx technology, to advance
blood safety. Cerus has demonstrated inactivation a broad range of viral and bacterial pathogens
that can be transmitted in blood component transfusions, including HIV, hepatitis viruses, the West
Nile Virus, other viruses and strains of both gram positive and gram negative bacteria. Unlike testing,
the system is not specific to individual pathogens and, as a result, has the potential to inactivate
emerging pathogens before they are identified as threats to the safety of the blood supply. Importantly,
it also prevents the proliferation of white blood cells, which are associated with a variety of
adverse transfusion reactions.
 
Cerus Corporation Announces Fourth Quarter And Year-End Results

CONCORD, Calif., January 29, 2004 – Cerus Corporation (Nasdaq: CERS) today announced results for the fourth quarter and year ended December 31, 2003.

The net loss for the fourth quarter of 2003 was $10.1 million, or $0.46 per share, compared to a net loss of $15.8 million, or $0.99 per share, for the fourth quarter of 2002. For the year ended December 31, 2003, the company reported a net loss of $58.3 million, or $3.01 per share, compared to a net loss of $57.2 million, or $3.61 per share, for 2002. The reduction in the net loss for the quarter was due primarily to increased funding received under cooperative agreements with the U.S. Armed Forces and reduced operating expenses. The increase in the net loss for the year was due primarily to interest expense accrued on a loan from Baxter Capital Corporation, a financial subsidiary of Baxter International Inc.

Total revenue from government grants, development agreements and product sales was $3.5 million for the fourth quarter of 2003, compared to $1.6 million for the fourth quarter of 2002. For the year ended December 31, 2003, total revenue was $9.7 million, which included $8.2 million of funding from the U.S. Armed Forces, compared to $8.5 million for 2002, which included a $5.0 million milestone payment from Baxter.

At December 31, 2003, the company had cash, cash equivalents and short-term investments of $110.0 million.

Loan principal and accrued interest under a credit facility with Baxter Capital Corporation is classified as a current liability on the balance sheet, due to a dispute concerning the timing of repayment.

Cerus and subsidiaries of Baxter International Inc. are collaborating on development of the INTERCEPT Blood System to enhance the safety of blood transfusions. The INTERCEPT Blood System for platelets is being commercialized in Europe. The product is not yet approved in the United States. In addition to the INTERCEPT Blood System, Cerus also is developing therapeutic and vaccine applications of its Helinx ® technology.

QUARTERLY CONFERENCE CALL
The company has scheduled its quarterly conference call for 4:30 p.m. EST today. Interested parties can access a live Internet broadcast at http://www.cerus.com/pages/IR/wc.html. For those unable to listen to the live broadcast, the call will be archived at www.cerus.com.

ABOUT CERUS
Cerus Corporation is developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. The INTERCEPT Blood System, which is being developed in collaboration with subsidiaries of Baxter International Inc., is based on the company's Helinx technology. The INTERCEPT Blood System is designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic and vaccine applications of Helinx technology to treat and prevent serious diseases.
 
ci lavora anche un italiano:D
Paolo Rebulla , M.D.
Director of Blood Transfusion and Transplantation Immunology,
Department of Blood Transfusion,
Tissue Repair and Transplantation
Ospedale Maggiore, Milan, Italy
 
Ciao Adolar.

con questi nr. e con l'attuale AT CERS continuerà ad essere come l'apparizione degli spiriti, tutti ne parlano quasi nessuno li ha visti :D
Ciao ;)
 
ragin' bull di gennaio.
Quarterly financials:

At December 31, 2003, the company had cash, cash equivalents and short-term investments of $110.0 million.

For the year ended December 31, 2003, the company reported a net loss of $58.3 million.

Cerus has enough cash to survive the next 2 years.

Stock price hugely undervalued.
 
Scritto da Grecale
Ciao Adolar.

con questi nr. e con l'attuale AT CERS continuerà ad essere come l'apparizione degli spiriti, tutti ne parlano quasi nessuno li ha visti :D
Ciao ;)
Ciao;)
bisogna un attimo valutare se nel giro di 2 anni questa melocola possa creare profitti. Vedo che la cosa interessa molto l'esercito USA, che è uno dei principali finanziatori.
 
3 mesi:)
 

Allegati

  • mchartisapi.png
    mchartisapi.png
    14,7 KB · Visite: 140
5 analisi tp annuale viene indicato a 5$
 
titolo sostenuto ;)
 

Allegati

  • 1080745019586.gif
    1080745019586.gif
    12,1 KB · Visite: 199
intraday adesso
 

Allegati

  • 1080760446766.gif
    1080760446766.gif
    14,3 KB · Visite: 186
nessuno seguì?:D
oggi 4,04 +10%
 
Indietro